Methods of assessing risk of and treating preeclampsia and subtypes thereof
AssigneesNx Prenatal Inc., The Brigham and Women's Hospital, Inc.
InventorsKevin P. ROSENBLATT, Thomas F. MCELRATH
Life of this patent
Estimating the term…
Abstract
Disclosed herein are CMP-associated proteins, collected between 10-12 weeks of gestation, that can be used to stratify the risk of later preeclampsia requiring delivery at <=35 weeks of gestation. For those that screen positive, clustering can be used to further characterize the putative subtype of the preeclampsia. Risk stratification and disease phenotype characterizations such as this can optimize prophylactic and therapeutic interventions.
Claims41
A method for determining a subtype of preeclampsia in a pregnant subject, the method comprising:
- (a) preparing a microparticle-enriched fraction from a blood sample from a pregnant subject at increased risk of preeclampsia;
- (b) determining a measure of a panel of microparticle-associated protein biomarkers in the fraction, wherein the panel includes at least one coagulation-related biomarker and/or at least one complement activity-related biomarker;
- and
- (c) assessing the form of preeclampsia based on the measure, wherein:
- altered expression of a coagulation-related biomarker indicates blood coagulation-associated preeclampsia;
- and altered expression of a complement activity-related biomarker indicates complement-type preeclampsia.
(canceled)
A method of treating a subtype of preeclampsia in a pregnant subject comprising:
- (a) determining whether the subject is at increased risk of coagulation-associated preeclampsia or complement activity-type preeclampsia, wherein determining comprises associating a measure of one or more protein coagulation-related biomarkers or one or more complement activity-related biomarkers with coagulation-associated preeclampsia or complement activity-type preeclampsia;
- and
- (b) treating the subject as follows:
- (1) if the subject is determined to be at increased risk of coagulation-associated preeclampsia, administering to the subject a therapeutic intervention to decrease abnormal blood coagulation;
- or
- (2) if the subject is determined to be at increased risk of complement activity-type preeclampsia, administering to the subject a therapeutic intervention to decrease abnormal complement activity.
A method for assessing risk of preeclampsia requiring delivery in <=35 weeks gestation, in a pregnant subject, the method comprising:
- (a) preparing a microparticle-enriched fraction from a blood sample from the pregnant subject;
- (b) determining a measure of one or more a panel of microparticle-associated protein biomarkers in the fraction, wherein the panel comprises one or more protein biomarkers arc selected from:
- (i) a protein biomarker of Table 2;
- and
- (ii) a protein biomarker of Table 3;
- and
- (c) assessing the risk of preeclampsia requiring delivery at <=35 weeks gestation based on the measure.
-15. (canceled)
The method of claim, wherein the panel comprises no more than any of 10, 9, 8, 7, 6, 5, or 4 protein biomarkers.
-27. (canceled)
-33. (canceled)
-40. (canceled)
-46. (canceled)
-66. (canceled)
A computer-implemented method for generating a model to assess a risk of preeclampsia, the computer-implemented method comprising:
- obtaining a dataset, the dataset comprising measurements associated with a plurality of biomarkers derived from each of a plurality of subjects;
- and
- implementing a machine learning analysis to associate a set of biomarkers within the plurality of biomarkers with preeclampsia, wherein implementing the machine learning analysis generates a model to assess the risk of preeclampsia, wherein the risk of preeclampsia is one or more of risk of preeclampsia requiring delivery in <=±weeks gestation, risk of blood coagulation-associated preeclampsia and risk of complement-activity related preeclampsia, wherein the set of biomarkers are selected from the biomarkers of Table 2, Table 3, and Table 4.
-71. (canceled)
A computer-implemented method of assessing a risk of preeclampsia in a subject, the computer-implemented method comprising:
- determining a quantitative measure of at least one biomarker in a sample;
- and
- executing a classification rule based on the quantitative measure,
- wherein the execution of the classification rule assesses the risk of preeclampsia in the subject (e.g. risk of preeclampsia requiring delivery in <=±weeks gestation, risk of blood coagulation-associated preeclampsia and/or risk of complement-activity related preeclampsia), and
- wherein the classification rule implements at least one of cut-offs, linear regression, binary decision trees, artificial neural networks, discriminant analyses, logistic classifiers, and support vector classifiers,
- wherein the at least one biomarker is selected from the biomarkers of Table 2, Table 3, and Table 4.
-75. (canceled)
Dependencies are inferred from the claim text.